Abstract：Background RNA-binding proteins （RBPs） are key mediators of RNA metabolism. IGF2BP proteins recognize mRNAs modified by methylation and lengthen their lifecycle in the context of stable ribonucleoprotein particles， thus promoting cancer progression. However， the impact of IGF2BP2/3 expression level in low-grade glioma （LGG） has not been thoroughly investigated.Objective This study assessed the prognosis value of IGF2BP2/3 in LGG using bioinformatics approaches.Methods We discussed the relationship between IGF2BP2/3 with LGG via analysis tools， including cBioPortal， TCGA， GTEx RNASeq data， TIMER， GDC， GEPIA， Metascape， and R package， including ggplot2， pheatmap， survival， and survminer.Results IGF2BP2 expression was lower in tumors than in normal tissues and GETx， while IGF2BP3 showed the opposite pattern. Nomogram was used to predict 1， 3， and 5 years of OS in LGG patients， and the nomogram integrated IGF2BP2/3 with other independent risk factors. GO and GSEA identified enrichment in the developmental process and cellular activity， respectively.Conclusion Our results suggest that IGF2BP2/3 is a potential molecular marker of poor prognosis in patients with LGG. At the same time， our study provides new insights into the LGG and provides potential biomarkers for progression and therapy.